SCHEMBL2237473

SCHEMBL2237473

CCCCCOC(=O)c1cc2c(cc1C(=O)OCCCCC)C(=O)NC2=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.57
MAPK1 P28482 2/20 0.57
TP53 P04637 1/20 0.57
CYP3A4 P08684 1/20 0.57
ALDH1A1 P00352 3/20 0.55
LMNA P02545 2/20 0.55
KDM4E B2RXH2 2/20 0.51
GPR84 Q9NQS5 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
POLB P06746 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MMP1 P03956 1/20 0.48
MMP9 P14780 1/20 0.48
MMP12 P39900 1/20 0.48
ESR1 P03372 1/20 0.48
AKR1C4 P17516 1/20 0.48
AKR1C3 P42330 1/20 0.48
AKR1C2 P52895 1/20 0.48
AKR1C1 Q04828 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2240586 0.98 TSHR (0.58) TSHRMAPK1TP53CYP3A4ALDH1A1
SCHEMBL20695608 0.83 TSHR (0.72) TSHRMAPK1TP53CYP3A4ALDH1A1
SCHEMBL2239053 0.82 ALDH1A1 (0.55) TSHRMAPK1TP53CYP3A4ALDH1A1
SCHEMBL2238761 0.82 ALDH1A1 (0.53) TSHRCYP3A4ALDH1A1LMNAKDM4E
SCHEMBL2244114 0.81 ALDH1A1 (0.56) TSHRALDH1A1LMNAESR1AKR1C4
SCHEMBL20695622 0.81 TSHR (0.73) TSHRMAPK1TP53CYP3A4ALDH1A1
SCHEMBL18106214 0.81 TSHR (0.73) TSHRMAPK1TP53CYP3A4ALDH1A1
SCHEMBL20695609 0.81 TSHR (0.73) TSHRMAPK1TP53CYP3A4ALDH1A1
SCHEMBL9799473 0.81 TSHR (0.73) TSHRMAPK1TP53CYP3A4ALDH1A1
SCHEMBL19348920 0.81 TSHR (0.73) TSHRMAPK1TP53CYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994330-B2 Oxidizing p-xylene to terephthalic acid using a catalyst having a dicarboximide skeleton; hydrothermally treating the product with hot water, decomposing and removing catalyst impurities DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2011-08-09 US disclosed
US-20080171881-A1 Method for Producing Organic Compound and Method for Decomposing Compound Having Dicarboximide Skeleton DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2008-07-17 US disclosed
EP-1870394-A1 METHOD FOR PRODUCING ORGANIC COMPOUND AND METHOD FOR DECOMPOSING COMPOUND HAVING DICARBOXYIMIDE SKELETON Daicel Chemical Industries, Ltd. (JP) 2007-12-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171881-A1 Method for Producing Organic Compound and Method for Decomposing Compound Having Dicarboximide Skeleton DHPS, OGDH, MCCC2 TSHR 4661/4885MAPK1 2785/4885TP53 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.